MUNDIPHARMA
16.1.2020 15:00:04 CET | Business Wire | Press release
Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com.sg .
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter , LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005483/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Type One Energy, Tokamak Energy, and AECOM Form the UK Infinity Fusion Consortium to Accelerate Development of a Commercial Fusion Power Plant in the United Kingdom6.5.2026 10:00:00 CEST | Press release
Type One Energy, Tokamak Energy, and AECOM today announced the UK Infinity Fusion Consortium to pursue development of the first private-sector-led fusion power plant project in the United Kingdom. Together, the companies intend to develop a fusion project that is commercially credible, deployable using existing enabling technologies, and capable of attracting private capital — consistent with the long-term goals of the government’s recently announced UK Fusion Strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506129586/en/ (From left to right) Warrick Matthews, CEO of Tokamak Energy; Chris Mowry, CEO of Type One Energy; and Troy Rudd, Chairman and CEO of AECOM sign the UK Infinity Fusion Consortium during His Majesty King Charles III’s visit to New York City. This announcement comes at a time of increasing U.S.-U.K. bilateral cooperation on fusion. His Majesty King Charles III said during his address to the United
59% of Organizations Made a "Bad AI Hire" in the Past Year, New TestGorilla Research Reveals6.5.2026 10:00:00 CEST | Press release
Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the Atlantic TestGorilla, the leading skills-based hiring platform, today released The State of Hiring for AI Fluency, revealing a fundamental shift in talent evaluation: AI fluency has overtaken domain expertise as the top hiring priority. 53% of hiring managers now prefer candidates with strong AI fluency over deep subject matter experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506155219/en/ TestGorilla's The State of Hiring for AI Fluency Report Reveals a Transatlantic Divide between US and UK: Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the A
Pure Energie Selects Kraken to Manage Wind, Solar and Storage6.5.2026 09:00:00 CEST | Press release
Kraken operating system to manage Pure Energie’s growing portfolio on one intelligent platformPure Energie to benefit from seamless co-ordination across customer load, wind, solar and batteries – maximizing asset value while helping to balance the grid20 sites to onboard in H1 2026, with further expansion planned Pure Energie, a Dutch clean energy company, has selected Kraken – the AI-powered operating system transforming global utilities – to manage and optimize its consumer, wind, solar and battery portfolio across the Netherlands. Kraken brings together grid-scale assets and consumer demand on the same platform, co-ordinating them as a single, intelligent portfolio. This enables Pure Energie to optimize demand and generation in real time – maximizing asset value and helping reduce imbalance costs. The partnership will deliver an energy management system which includes retail balancing, day-ahead curtailment, intraday trading, imbalance optimization, and ancillary market access, alon
Thredd and Currensea Expand Strategic Partnership to Power Next Phase of Growth6.5.2026 09:00:00 CEST | Press release
Four-year renewal builds on long-standing collaboration supporting the payments technology platform behind co-branded reward-earning debit cards and the UK’s top-rated travel spending card Thredd, the AI-first issuer processing platform, today announced the renewal and extension of its longstanding partnership with Currensea, the market-leading payments technology platform. The new agreement extends the relationship for an additional four years, reinforcing a collaboration that has been in place since 2019. Currensea has built a strong reputation among travellers with its multi-bank travel card that links directly to customers’ existing bank accounts, offering competitive FX rates without the need to preload funds. In recent years, Currensea has expanded its offering through co-brand partnerships with leading global travel and hospitality brands, including Hilton Hotels, Marriott Bonvoy and United Airlines, allowing cardholders to earn competitive rewards on their day-to-day debit spen
AMINA Becomes First Bank to Support Canton Coin Trading and Custody6.5.2026 08:30:00 CEST | Press release
Swiss-regulated AMINA provides clients with regulated access to the network that DTCC, Visa, BitGo, and others are building on AMINA Bank AG ("AMINA"), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first bank to support Canton Coin (CC), the native token of Canton Network, offering custody and trading services to its clients. Canton Network is a public, privacy-preserving blockchain built for capital markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505860056/en/ AMINA Becomes First Bank to Support Canton Coin Trading and Custody Canton has gained significant institutional momentum in recent months, attracting TradFi and DeFi organizations, including the DTCC, Visa, and BitGo, that are building next-generation settlement, tokenisation, custody, and collateral workflows on the network. Canton is also developing an on-chain capital markets ecosystem t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom